Good afternoon, everyone, and thank you for joining us. Welcome to the BioLife Solutions Q3 2024 Shareholder and Analyst Conference Call. I will now hand the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please proceed.

Thank you, operator. Good afternoon, everyone, and thank you for joining the BioLife Solutions 2024 third quarter earnings conference call. On the call with me today is Rod de Greef, CEO and Chairman of the Board. We will cover business highlights and financial performance for the quarter, and provide an update on our full year 2024 revenue guidance. Earlier today, we issued a press release announcing our financial results and operational highlights for the third quarter of 2024, which is available at biolifesolutions.com. As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC filings. These statements speak only as of the date given, and we undertake no obligation to update them. We will also speak to non-GAAP or adjusted results. Reconciliations of GAAP to non-GAAP or adjusted financial metrics are included in the press release we issued this afternoon. Now I'd like to turn the call over to Rod de Greef, Chairman and CEO of BioLife.

Thanks, Troy. Good afternoon, and thank you for joining us for BioLife’s third quarter 2024 earnings call. I'm pleased to report another strong quarter, marking our fourth consecutive period of sequential revenue growth and a strong rebound year-over-year. This further demonstrates our belief that the macro environment as it relates to the bioproduction subsector in which we operate is continuing to improve. Our Cell Processing platform revenue totaled $19 million, representing a sequential increase of 6% and up 43% compared to the third quarter of 2023. This is a high margin business, and we see that profitability directly reflected in our financial performance this quarter with continued margin expansion. Adjusted gross margin for Q3 came in at 54%, up from 44% in the same period last year, and we delivered an adjusted EBITDA margin of 20% compared to 6% last year. These results underscore the attractiveness of our market-leading cell processing portfolio as we continue to drive both top line growth and margin expansion through our proprietary high margin recurring revenue streams. Earlier today, we announced the strategic divestiture of our SciSafe bio storage business, which serves as yet another pivotal step in our evolution. I will discuss this in further detail momentarily, but I'm confident that with our streamlined structure and fortified balance sheet, BioLife is better positioned than ever to deliver long-term value for our shareholders. Looking ahead, based on the strength of our Q3 results combined with what we're seeing as the last quarter of the year unfolds, we have modestly increased our cell processing revenue guidance, which Troy will speak to later in the call. We believe that the momentum we've realized throughout this year, both in terms of revenue growth and margin expansion, provides us with a solid jumping-off point from which to enter 2025. Staying focused on our cell processing revenue, our biopreservation media products, which account for the vast majority of the platform's revenue, had a strong quarter-over-quarter increase. This was somewhat offset by an expected timing-related sequential decline in other products. Historical biopreservation media revenue trends remain consistent this quarter, with our top 20 customers accounting for approximately 80% of media revenue. An estimated 60% of the biopreservation media revenue came from direct customers in the quarter, and of that amount, customers with approved therapies totaled approximately 40%. We believe our biopreservation media products are embedded in more than 70% of relevant, commercially sponsored CGT clinical trials, which provides an encouraging indicator for sustainable future growth. In Q3, the CGT regulatory environment continued the forward momentum that started last year, with our biopreservation media embedded in two newly approved therapies during the quarter. This brings us to a total of 17 unique therapies that incorporate our market-leading biopreservation media. Further, we see six additional product approvals, geographic expansions, or new indications occurring in the next 12 months. Looking strategically at the road ahead, we will continue to refocus our efforts and allocate our capital toward our proprietary, high-growth, high-margin cell processing portfolio of products. This morning's announcement of the sale of our SciSafe biostorage business and a $73 million all-cash transaction is a pivotal step in the evolution of BioLife into a pure-play CGT tools provider, driven by our recurring reagents business. Not only does the divestiture fortify our balance sheet, but it also frees up significant operational bandwidth, which will be redeployed to support the growth of our core cell processing products. During our recent strategic review, we determined that our biostorage business, which accounted for $16 million in Q3 year-to-date revenue, was furthest away from our core competencies and expertise. In addition, we believe the level of capital required for consolidation and future growth would be better allocated to supporting and expanding our cell processing product portfolio, specifically our biopreservation media products. As a result of a more streamlined product portfolio, we have consolidated all our sales and marketing efforts under Todd Berard, who has moved into the newly created role of Chief Commercial Officer. Todd, who has served as our Chief Marketing Officer, has been with BioLife for more than 10 years and has a deep understanding of the CGT market, our product line, as well as established relationships with our larger key customers. Garrie Richardson, who has been our Chief Revenue Officer for the last year and the original founder of SciSafe, has become the CEO of the now independent SciSafe. I would like to personally thank Gary and the entire SciSafe team for their contributions to BioLife over the last 4 years and wish them a bright and successful future. With that said, we realize the job is not done and we're committed to exiting the remaining freezer business. Although CBS generated positive adjusted EBITDA for the quarter and represents less than 13% of sales, it has dragged on long-term margins. We are making steady progress and will provide updates as events warrant. Our vision is to evolve BioLife into a pure-play CGT tools and reagents provider, so we can fully leverage our core competencies and the distinct market leadership of our biopreservation media. We believe this approach represents the strongest path to delivering sustained shareholder value as we drive both revenue growth and profitability into 2025 and beyond. Now I'll turn the call over to Troy, who will provide a review of our Q3 financial results.

Thank you, Rod. Today, we will be reviewing current and prior period financials from continuing operations for Q3 2024, which excludes Sterling. We reported Q3 revenue from continuing operations of $30.6 million, representing an increase of 30% year-over-year. The year-over-year increase was primarily related to a 43% increase in our cell processing platform. Total revenue was up sequentially from Q2 2024 by $2.2 million, or 8%, primarily driven by a double-digit sequential increase in biopreservation media revenue. GAAP gross margin for Q3 2024 was 51%, compared with 48% in Q3 2023. Adjusted gross margin for the third quarter was 54%, compared with 44% in the prior year. The increase was primarily due to a more favorable product mix and better utilization at our SciSafe biorepository facilities. GAAP operating expenses for Q3 2024 were $32.1 million versus $39 million in Q3 2023. The decrease compared to the prior year was largely due to a reduction in headcount that took place at the end of Q3 2023, in addition to an asset impairment of $8.3 million related to our freezer business that the company took in Q3 2023. Adjusted operating expenses for Q3 2024 totaled $17.2 million compared with $18.7 million in the prior year. The decrease is primarily due to lower personnel costs from the Q3 2023 reduction in force and continued focus on expenses. GAAP operating loss for Q3 2024 was $1.6 million versus $15.5 million in the prior year. Our adjusted operating loss for the third quarter of 2024 was $600,000 compared with $8.3 million in Q3 2023. The decrease in operating loss was primarily due to an $8.3 million impairment the company took in Q3 2023 related to our freezer business. Our GAAP net loss was $1.7 million or $0.04 per share in Q3 2024 compared to $15.8 million or $0.36 per share in the prior year. The decrease in net loss was primarily due to an $8.3 million impairment the company took during Q3 2023 related to our freezer business and a $4.5 million improvement in gross margin. Adjusted EBITDA for the third quarter of 2024 was $6.1 million, or 20% of revenue, compared with $1.4 million, or 6% of revenue, in the prior year. Adjusted EBITDA increased from the prior year due to a $4.5 million improvement in gross margin, driven by increased sales of biopreservation media and lower personnel costs. Our adjusted EBITDA increased $2.3 million sequentially from Q2, 2024, primarily due to increased sales of biopreservation media. As Rod mentioned, earlier today we announced the sale of our SciSafe biostorage business, and we issued an 8-K earlier today, which included pro forma's without SciSafe in our financial results, and includes GAAP to non-GAAP reconciliations. For the 6-month period ending June 30, 2024, our revenue without SciSafe would have been $44.7 million versus our reported results of $55.1 million. Our adjusted gross margin without SciSafe would have been 60% versus 53% reported, and our adjusted EBITDA would have been 13% versus 15% reported. Although there was a slight decrease in our adjusted EBITDA profile for the first half of 2024 without SciSafe, we believe we will have a stronger EBITDA profile going forward without SciSafe as media revenue increases, which has a significant flow-through to our bottom line. In addition, there will be cost savings going forward by consolidating our sales and marketing department under Todd Berard. Turning to our balance sheet. Our cash and marketable securities balance reported as of September 30, 2024, was $39.3 million, compared with $36.9 million as of June 30, 2024. This does not include any proceeds from the sale of SciSafe. The total sequential cash increase of $2.4 million was primarily driven by cash provided by operation activities of $6.8 million, partially offset by a $2.5 million principal payment on our term loan and $1.4 million in capital expenditures. Our SVB long-term debt balance was $17.5 million. We expect to continue making quarterly repayments of $2.5 million going forward. Turning to 2024 revenue guidance. We are updating our previous guidance, which is based on expectations for our cell processing platform, EVO, ThawSTAR, and 10 months of revenue from SciSafe, and does not include any revenue from CBS. As has been the case throughout this year, the BioStorage Service Platform guidance includes the ThawSTAR automated filing devices product line. Our total revenue is expected to be $98 million to $100 million, a reduction from our original guidance of $99 million to $101 million, reflecting an increase in guidance for our cell processing platform of $2 million, which is offset by $3 million related to the decrease in expected storage revenue given the sale of SciSafe. Our cell processing platform is expected to contribute $72 million to $73 million, or 9% to 11% growth over 2023. This is an increase of $2 million on both the low and high end of our previous guidance. Our biostorage services platform is expected to contribute $26 million to $27 million, which includes 10 months of SciSafe revenue. Finally, in terms of our share count, as of November 5th, we had 46 million shares issued and outstanding, and 48.5 million shares on a fully diluted basis. Now I'll turn the call back to the operator to open up for questions.

Hi. This is Hannah on for Jacob. Thanks for taking the questions. To start with the SciSafe sale, can you just frame up what pro forma gross margins look like, and then how should we think about any OpEx savings and depreciation going forward?

Yes, we issued an 8-K earlier today that lays out all the details for different prior periods, 2021 up to the 6 months ended in 2024. So you'll see in the 6 months of 2024, adjusted gross margin without SciSafe of 60% and an adjusted EBITDA margin of 13%. However, going forward, we expect that to have a very minimal impact on our adjusted EBITDA profile.

All right, thanks. And then I know you're not guiding into 2025, but with destocking, we've seen some swings in revenue and growth over the last year. And I'm just curious if you could frame up how we should think about long-term growth from here? And if there are any puts and takes we should be aware of as we're starting to think about 2025.

Yes, I believe it would be best to wait for our formal guidance, which we will release in early January before the JPM conference. Your observation regarding last year's Q2 to Q3 is valid. However, when considering Q3 onward, we have experienced four consecutive quarters of growth. While this growth may not continue in a strict sequential manner, we do anticipate growth in 2025. We also feel that the destocking phase is largely behind us at this time.

Awesome. Thanks. I'll leave it there.

The next question comes from Matt Stanton from Jefferies. Please go ahead.

Hey, thanks. Rod, you talked about post SciSafe sale, kind of being able to streamline the structure, balance sheet in a better position to deliver value. Just talk about some of the areas of focus post the sale, whether it would be looking to do additional deals, capacity adds around the media business, just like where the focus will be strategically post the SciSafe sale there. Thank you.

You bet. The focus is in general around our cell processing product line, which would be the biopreservation media and the Sexton tools that we acquired several years back, which would include HPL, the CryoSeal product line, which includes the newly introduced CryoCase, as well as the CT5 automated fill machine. So those products are going to get the lion share of our attention. With respect to capacity, in particular, we definitely have some capacity needs coming into the next couple of years with respect to biopreservation. That sale of SciSafe provides us with the capital to do so. To the extent that we would look at anything inorganic or any kind of transactions from an M&A perspective, I think that there's a place for that. But I think that our criteria going forward around this issue is very stringent. And I think at this point, the only thing that we would look to do needs to have a direct impact on maintaining or expanding our market leadership position in those cell processing tools. So that would be biopreservation media. It would be HPL, et cetera. The other, I think, key criteria is that whatever we do does not negatively impact the margin expansion trajectory that we're on right now, because that's a critical objective for us to increase that margin both on the growth side and on the adjusted EBITDA side.

Awesome. Thanks for that. And then, I guess, going back over to Sexton, the launch of the new CryoCase, just any update there? I think it's commercially available this quarter, for those that have trials that had it in their hands, kind of feedback, whether that be biopharma customers, CROs, CDMOs, folks like that. And if we look out a year from now, what are you going to quantify as a successful launch of that product here? Thank you.

Yes, I think the initial impression from a handful of really key customers is positive. There's a pretty significant validation process that these customers need to go through to consider this. It's not insurmountable in any way, shape or form, but the initial feedback is good and I would expect to start to see revenue generated at any kind of material level toward the end of next year, the back half of next year. But we may end up talking about some sort of revenue contribution in our guidance, but at this point in time, Matt, it's a little early.

Super. Thank you. I'll leave it there. Appreciate it.

You bet.

The next question comes from Brendan Smith from TD Cowen. Please go ahead.

Hi, guys. Thanks for taking the question. Congrats on the solid quarter. Maybe just a quick one from us, kind of building on the previous questions here, but can you expand a bit on what some of the specific levers are within the cell processing platform that you can pull heading into next year just to help shore up some of that top line growth in 2025? And I guess what I'm really getting at is that I'm wondering what kinds of macro trends you're seeing specifically and how some of those could be leveraged as you kind of continue to restructure the business internally? Thanks.

Yes. So, I think that as we've talked about a couple of key factors. One would be the fact that 80% of our media revenue comes from 20 customers. That's a really key fact. And so, to some degree, our success is based on their success, right? So that's an important thing. I think that the opportunity that we have to drive revenue past the sort of natural pull that would happen from these large customers is to deepen our relationship with our distributors, which we're working on doing. There are some pricing opportunities that we have also that we have so far had some good initial success on in terms of reducing historical legacy discounts. And I think the other area where we can actually have potentially material impact on driving revenue and cell processing is that cross-selling feature of the Sexton tool products into our existing customer base. And there are a number of different evaluations going on for different products with different customers, and we would expect to see some revenue come out of that toward the end of next year in particular, CryoCase being one of those as I mentioned earlier.

Got it. Very helpful there. Thank you.

You bet.

The next question comes from Anna Snopkowski from KeyBanc. Please go ahead.

Hi. Thanks for taking my question. This is Anna Snopkowski on for Paul. My first question is regarding the announced divestiture of SciSafe. You talked about this a little during your prepared remarks, but I was wondering if this changes your strategy at all going forward specifically on the potential divestiture of CBS.

Sorry, I think in terms of CBS, I'll just speak to that specifically. We are definitely in the throes of a transaction there. We're pretty close, and we are committed, as we have been for some time, to exiting that business through a transaction. So stay tuned for that. In terms of the strategic impact of the sale of SciSafe, I think we've tried to be clear about the fact that the focus of the company going forward is going to be on the proprietary higher growth, higher margin recurring revenue products that primarily are in the cell processing platform as it's defined today.

Makes sense. And then just looking at cell processing, is there anything you would call out in terms of customer destocking or pushing out orders? Or would you say that is largely normalized within the segment?

Yes, we believe that Q3 was a normalized quarter for us with respect to that. And destocking, as we've talked about in the past, really got behind us sort of Q1. We had one customer in Q2, but that customer started to take product in Q3. So, we do believe it's behind us, barring some sort of industry-wide issue that pops up here again.

Thank you.

The next question comes from Matt Hewitt from Craig-Hallum Capital Group. Please go ahead.

Good afternoon and congratulations on a strong quarter. Maybe first up, and thank you for pointing out the 8-K, I think you mentioned 60% roughly gross margins, absent SciSafe contribution in the first half of the year. How should we be thinking about your margin trajectory as we look out into 2025 and beyond? Where could your margins go, particularly on the gross margin side?

Yes, I'll take that one. So you're right, 60% for the first half, right? And what we've been talking about how key the growth of the media revenue is to our financial profile, not only on the growth side, but on the adjusted EBITDA side. As you recall, historically, before we did any acquisitions, the media gross margin was roughly 70%. And then some of the initiatives we're working on internally to help expand that margin even further to drive our overall consolidated gross margin into, call it the upper 60s in the not so distant future.

Excellent. And then just regarding the third quarter here, obviously a nice pop, both sequentially and year-on-year for the media business. Was that just a function of the two approvals in the quarter, getting some extra stocking there or was there something else that kind of drove that increase? Thank you.

Yes, it was not related to the two approvals we received. Typically, there is a significant gap between those approvals and the resulting demand. It primarily stemmed from strong demand among our top 20 customers, which was very positive for us. This situation, along with our expectations for Q4, is what prompted us to raise the cell processing guidance by $2 million.

That's great. Thank you.

Thank you.

Our next question comes from Thomas Flaten from Lake Street. Please go ahead.

Hey, Rod, just to follow-up on that last comment. Can you comment qualitatively on some of the smaller customers, the earlier stage biotechs, academia, et cetera, how are they coming along from a macro perspective?

I believe they are progressing well. We assess this primarily through our larger distributors, particularly the top three, as indicators for the smaller customers. We have observed good sequential growth from these distributors, with one exception, which was largely due to renegotiating their agreement on pricing rather than a decline in demand. Overall, we feel confident that the demand is strong across the board, not only among direct customers but also with distributors representing smaller academic and early-stage companies. Overall, things are moving positively for us.

Excellent. And then with respect to longer term growth within cell processing, how relevant is Asia, for example, in terms of geographic expansion to help keep those long-term growth rates up?

Less than 5% we believe of our revenue comes out of China. Right now, specifically China, even less for the rest of Asia. So while it's an important piece of business for us, it's not material in the sense of the things that are going on, whether it's the Biosecure Act or other things like that, we do not see any impact of that on us going forward, at least at this point in time.

Got it. Thanks so much.

You bet.

The next question comes from Yi Chen from H.C. Wainwright. Please go ahead.

Sorry. So sorry it was. Sorry, it's Jade on for Yi Chen. So thank you for taking my question. Sorry for being on mute. So can you just quickly more on those biggest three distributors you were talking about. Do you have any idea of the approximate number of individual customers that represents or ...?

Yes, collectively, we think it's in the neighborhood of 4,000 to 5,000 worldwide.

Okay, great. And so I think I heard you say earlier it was 17 approved CGTs currently using the services?

That's correct. It's a bio-preservation media, particularly.

Do you expect that number to change in the next 6 months or so, or are most things further back in the queue, do you think?

No, as we stated earlier, we do expect six additional, whether they're unique therapies or geographic expansions, indications, new indications for the same therapy, or movement up the line of treatment. We expect six of those occurrences in the next 12 months or so, 9 to 12 months.

Okay. All right. Thank you so much.

You bet.

This concludes our question-and-answer session. I would like to turn the conference back over to Rod de Greef for any closing remarks.

Thank you, operator. It's been a little over a year since I came back into an operating role with the company and as I look back I'm very pleased with the progress the BioLife team has made. In the last 12 months we focused the bulk of our efforts on our proprietary higher growth, higher margin core cell processing platform. This has allowed us to reestablish sequential revenue growth and streamline our operations, both of which have driven solid margin expansion, especially at the adjusted EBITDA level. With the strengthened balance sheet and an even more focused product portfolio, we're well-positioned to leverage our market-leading position in biopreservation to drive the adoption of the other high margin recurring revenue cell processing tools in our portfolio, which we believe will drive continued revenue growth and increased profitability. We appreciate your time today and look forward to updating you on our continued progress on future calls and meeting with some of you at upcoming investor conferences during the coming months. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.